CDTTWNCM

CDT Equity Inc.

-2.9% · 90d

$0.01

+0.00 (+0.00%)

News

No News Yet

Press releases and SEC filings for CDTTW will appear here as they are published.

Check back later for updates

Key Data

Market Cap—

Open$0.01

Prev Close$0.01

Day Range$0.01 – $0.01

52W Range$0.01 – $0.01

Volume7

P/E (TTM)—

EPS—

Dividend Yield—

Beta2.08

About

CDT Equity Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It has strategic services agreement with formulation development CDMO Agility Life Sciences to develop new solid oral-dosage form products. The company was formerly known as Conduit Pharmaceuticals Inc. and changed its name to CDT Equity Inc. in August 2025. The company was founded in 2019 and is based in Naples, Florida.

4 employees

www.conduitpharma.com

Top Institutional Holders

As of 2025-12-31 · prior 2025-09-30

BOOTHBAY FUND MANAGEMENT, LLC$320,000

250,000 sh0.0%

Saba Capital Management, L.P.$4,208

765,000 sh0.0%

Polar Asset Management Partners Inc.$5,225

950,000 sh0.0%

TORONTO DOMINION BANK$3,777

755,391 sh-0.0%

MMCAP International Inc. SPC$3,850

700,000 sh0.0%

See all holders →

Quarterly Financials

09/25

Revenue Net Income